RGNX (STOCKS)
REGENXBIO Inc.
$10.420000
-0.490000 (-4.49%)
Prev close: $10.910000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Curran M. Simpson
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $770.82M
- Employees
- 353
- P/E (TTM)
- -2.88
- P/B (TTM)
- 8.23
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
6
Strong Buy
11
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2026 (Q2)
|
$0.43 | $0.06 | +0.3708 | +626.35% |
|
Mar 2026 (Q1)
|
$-1.72 | $-1.37 | -0.3543 | -25.94% |
|
Dec 2025 (Q4)
|
$-1.30 | $-0.98 | -0.3248 | -33.31% |
|
Sep 2025 (Q3)
|
$-1.20 | $-1.33 | +0.1316 | +9.88% |
Financial Statements
| Revenues | $174.48M |
| Benefits Costs and Expenses | $354.83M |
| Costs And Expenses | $338.63M |
| Nonoperating Income/Loss | -$32.29M |
| Operating Expenses | $338.63M |
| Depreciation and Amortization | $15.37M |
| Research and Development | $229.14M |
| Other Operating Expenses | $101.77M |
| Operating Income/Loss | -$164.15M |
| Income/Loss From Continuing Operations After Tax | -$196.43M |
| Income/Loss From Continuing Operations Before Tax | -$180.35M |
| Net Income/Loss | -$196.43M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$196.43M |
| Net Income/Loss Available To Common Stockholders, Basic | -$196.43M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$3.78 |
| Diluted Earnings Per Share | -$3.78 |
| Basic Average Shares | 104,374,000 |
| Diluted Average Shares | 104,374,000 |
| Assets | $386.62M |
| Current Assets | $236.16M |
| Cash | $105.50M |
| Accounts Receivable | $106.75M |
| Prepaid Expenses | $11.90M |
| Other Current Assets | $12.00M |
| Noncurrent Assets | $150.46M |
| Fixed Assets | $98.45M |
| Other Non-current Assets | $52.01M |
| Liabilities | $314.85M |
| Current Liabilities | $82.62M |
| Accounts Payable | $15.55M |
| Wages | $12.96M |
| Other Current Liabilities | $54.12M |
| Noncurrent Liabilities | $232.23M |
| Equity | $71.77M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $71.77M |
| Liabilities And Equity | $386.62M |
| Net Cash Flow From Operating Activities | -$246.67M |
| Net Cash Flow From Operating Activities, Continuing | -$246.67M |
| Net Cash Flow From Investing Activities | $216.34M |
| Net Cash Flow From Investing Activities, Continuing | $216.34M |
| Net Cash Flow From Financing Activities | -$12.74M |
| Net Cash Flow From Financing Activities, Continuing | -$12.74M |
| Net Cash Flow | -$43.07M |
| Net Cash Flow, Continuing | -$43.07M |
| Comprehensive Income/Loss | -$196.56M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$196.56M |
| Other Comprehensive Income/Loss | -$125.00K |